Literature DB >> 16008823

Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus.

G J Guillemin1, B J Brew, C E Noonan, O Takikawa, K M Cullen.   

Abstract

The present immunohistochemical study provides evidence that the kynurenine pathway is up-regulated in Alzheimer's disease (AD) brain, leading to increases in the excitotoxin quinolinic acid (QUIN). We show that the regulatory enzyme of the pathway leading to QUIN synthesis, indoleamine 2,3 dioxygenase (IDO) is abundant in AD compared with controls. In AD hippocampus, both IDO- and QUIN-immunoreactivity (-IR) was detected in cortical microglia, astrocytes and neurones, with microglial and astrocytic expression of IDO and QUIN highest in the perimeter of senile plaques. QUIN-IR was present in granular deposits within the neuronal soma of AD cortex and was also seen uniformly labelling neurofibrillary tangles. Our data imply that QUIN may be involved in the complex and multifactorial cascade leading to neuro-degeneration in AD. These results may open a new therapeutic door for AD patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16008823     DOI: 10.1111/j.1365-2990.2005.00655.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  108 in total

1.  Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface.

Authors:  Andrew H Miller
Journal:  Brain Behav Immun       Date:  2008-09-03       Impact factor: 7.217

2.  Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study.

Authors:  Vincent Chouraki; Sarah R Preis; Qiong Yang; Alexa Beiser; Shuo Li; Martin G Larson; Galit Weinstein; Thomas J Wang; Robert E Gerszten; Ramachandran S Vasan; Sudha Seshadri
Journal:  Alzheimers Dement       Date:  2017-06-08       Impact factor: 21.566

Review 3.  Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise.

Authors:  Jennifer C Felger; Andrew H Miller
Journal:  Front Neuroendocrinol       Date:  2012-09-21       Impact factor: 8.606

Review 4.  Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

Authors:  J C Felger; F E Lotrich
Journal:  Neuroscience       Date:  2013-05-03       Impact factor: 3.590

Review 5.  The involvement of astrocytes and kynurenine pathway in Alzheimer's disease.

Authors:  Ka Ka Ting; Bruce Brew; Gilles Guillemin
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

6.  Viable mouse gene ablations that robustly alter brain Aβ levels are rare.

Authors:  Jeremy H Toyn; Xu-Alan Lin; Mark W Thompson; Valerie Guss; Jere E Meredith; Sethu Sankaranarayanan; Nestor Barrezueta; John Corradi; Antara Majumdar; Daniel L Small; Melissa Hansard; Thomas Lanthorn; Ryan S Westphal; Charles F Albright
Journal:  BMC Neurosci       Date:  2010-11-05       Impact factor: 3.288

7.  Characterisation of the expression of NMDA receptors in human astrocytes.

Authors:  Ming-Chak Lee; Ka Ka Ting; Seray Adams; Bruce J Brew; Roger Chung; Gilles J Guillemin
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

8.  Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease.

Authors:  Ka Ka Ting; Bruce J Brew; Gilles J Guillemin
Journal:  J Neuroinflammation       Date:  2009-12-10       Impact factor: 8.322

9.  The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.

Authors:  Abdur Rahman; Kaka Ting; Karen M Cullen; Nady Braidy; Bruce J Brew; Gilles J Guillemin
Journal:  PLoS One       Date:  2009-07-22       Impact factor: 3.240

10.  CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression.

Authors:  C L Raison; R Dantzer; K W Kelley; M A Lawson; B J Woolwine; G Vogt; J R Spivey; K Saito; A H Miller
Journal:  Mol Psychiatry       Date:  2009-11-17       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.